• Novo Holdings portfolio company Hemab Therapeutics completed a Nasdaq IPO on May 1, 2026, raising $346.7 million.
• Nearly 17 million shares sold in an oversubscribed offering priced above the marketed range; stock closed up nearly 90% on day one.
• Proceeds earmarked to advance clinical trials for prophylactic treatments targeting rare bleeding and thrombosis disorders.
• FDA granted Breakthrough Therapy Designation in March 2026 for lead asset sutacimig to prevent bleeding episodes in Glanzmann thrombasthenia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.